Some risk factors for epithelial ovarian cancer are modifiable, according to a study published online Jan. 6 in the ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

The type of ovarian cancer that is drawing researchers' attention is formally known as high-grade serous ovarian cancer, or HGSOC. Doctors also refer to it as epithelial high-grade serous ovarian ...

Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. As we near the end of 2024, CURE is looking back at ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs ...